Search Results

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05%, a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.

The Ritedose Corporation, the leading contract development and manufacturing organization specializing in sterile Blow Fill Seal production, announces a significant expansion of its production capabilities to meet the demand for ophthalmic and respiratory medications.

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

NanoVibronix, Inc. (NASDAQ: NAOV) today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH (“APOGEPHA”) in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European markets.